Market Spotlight: Renal Disease


Report
52 Pages
March 2021
Region: Global
Citeline
ID: 5310263

This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2018, there were approximately 738.0 million prevalent cases of chronic kidney disease (all stages) in adults aged 20 years and over worldwide. This figure is forecasted to increase to 819.5 million by 2027.
The publisher estimates that in 2018, there were 166.6 million cases (22.6%) in stage 1, 185.7 million cases (25.2%) in stage 2, 361.8 million cases (49.0%) in stage 3, 19.0 million cases (2.6%) in stage 4, and 4.8 million cases (0.4%) in stage 5.
The approved drugs in the renal disease space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being intravenous, intramuscular, and subcutaneous formulations.
The largest proportion of industry-sponsored drugs in active clinical development for renal disease are in Phase I, with only one drug in the NDA/BLA stage.
Therapies in the pipeline for renal disease focus on a wide variety of targets. The majority of these therapies are administered orally, with the remainder being intravenous, subcutaneous, hemoperfusion, intramuscular, and topical formulations.
High-impact upcoming events for drugs in the renal disease space comprise topline Phase II trial results for suramin and ANG3777; topline Phase III trial results for Sibnayal, veverimer, recAP, and Jardiance; and an expected PDUFA date for Farxiga.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for renal disease have been in the early and mid-phases of development, with 56% of trials in Phase I–II, and 44% in Phase III–IV.
The US has a substantial lead in the number of renal disease clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
Clinical trial activity in the renal disease space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for renal

OVERVIEWKEY TAKEAWAYS

DISEASE BACKGROUND

Disease definition
Patient segmentation
Symptoms
Risk factors
Diagnosis

TREATMENT

Treatment of acute kidney injury
Treatment of chronic kidney disease

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Veverimer for Renal Disease (December 8, 2020)
Veverimer for Renal Disease (October 20, 2020)
Farxiga for Renal Disease (August 30, 2020)
Veverimer for Renal Disease (August 21, 2020)
Farxiga for Renal Disease (July 28, 2020)
Veverimer for Renal Disease (July 14, 2020)
Farxiga for Renal Disease (March 30, 2020)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

New To The Review Queue
Farxiga BTD Rests On Renal Outcomes Trial DAPA-CKD
FDA Clears Medtronic’s CRRT System For Pediatric Kidney Disease

LICENSING AND ASSET ACQUISITION DEALS

VTv Licenses Renal Disease Candidate To Anteris
Spectrum Licenses CKD Therapy To Unicycive
AstraZeneca Likes Sound Of Silence's Science
Deals Shaping The Medical Industry, February 2020

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status
Sponsors by phase
Recent events

BIBLIOGRAPHY

Prescription information

APPENDIX

LIST OF FIGURES

Figure 1: Trends in prevalent cases of chronic kidney disease, 2018–27
Figure 2: Overview of pipeline drugs for renal disease in the US
Figure 3: Pipeline drugs for renal disease, by company
Figure 4: Pipeline drugs for renal disease, by drug type
Figure 5: Pipeline drugs for renal disease, by classification
Figure 6: Farxiga for Renal Disease (August 30, 2020): Phase III - DAPA-CKD
Figure 7: Farxiga for Renal Disease (July 28, 2020): Phase III - DAPA-CKD
Figure 8: Key upcoming events in renal disease
Figure 9: Clinical trials in renal disease
Figure 10: Top 10 drugs for clinical trials in renal disease
Figure 11: Top 10 companies for clinical trials in renal disease
Figure 12: Trial locations in renal disease
Figure 13: Renal disease trials status
Figure 14: Renal disease trials sponsors, by phase

LIST OF TABLES

Table 1: Prevalent cases of chronic kidney disease, 2018–27
Table 2: Prevalent cases of chronic kidney disease, by stage, 2018
Table 3: Marketed drugs for renal disease
Table 4: Pipeline drugs for renal disease in the US
Table 5: Veverimer for Renal Disease (December 8, 2020)
Table 6: Veverimer for Renal Disease (October 20, 2020)
Table 7: Farxiga for Renal Disease (August 30, 2020)
Table 8: Veverimer for Renal Disease (August 21, 2020)
Table 9: Farxiga for Renal Disease (July 28, 2020)
Table 10: Veverimer for Renal Disease (July 14, 2020)
Table 11: Farxiga for Renal Disease (March 30, 2020)
Table 12: Historical global sales, by drug ($m), 2015–19
Table 13: Forecasted global sales, by drug ($m), 2021–25

Table of Contents

Related Topics

Related Reports

Diabetic Kidney Disease (DKD) - Market Insight, Epidemiology and Market Forecast - 2032

Renal Anemia - Pipeline Insight, 2024

Acute Renal Failure (ARF) (Acute Kidney Injury) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update

End Stage Renal Disease Market Size, Share & Trends Analysis Report By Treatment (Transplant, Dialysis), By Region (APAC, North America, MEA, Europe, Latin America), And Segment Forecasts, 2023 - 2030

End Stage Renal Disease (ESRD) Drug Global Market Report 2024